Idera Pharmaceuticals Presents Pre-Clinical Data Demonstrating Potential for Tilsotolimod (IMO-2125) in Combination with Chec...
April 17 2018 - 7:00AM
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage
biopharmaceutical company focused on the discovery, development and
commercialization of novel oligonucleotide therapeutics for
oncology and rare diseases, today is reporting pre-clinical data
from a study evaluating a combination regimen that involved the
TLR-9 agonist tilsotolimod (IMO-2125) and checkpoint inhibitors
targeting two negative immune regulators, IDO-1 and PD-1 to
eliminate established tumors in syngeneic tumor models at the AACR
2018 Annual Meeting being held in Chicago, IL.
In the poster presentation entitled, “Triple combination of
tilsotolimod, epacadostat and anti-PD-1 antibody demonstrates
maximal antitumor efficacy and eradicates large established tumors
in preclinical models,” Daqing Wang, Ph.D., Principal Scientist
& Group Leader, Idera Pharmaceuticals, presented results from
this pre-clinical study.
The key findings in Dr. Wang’s presentation were that
intratumoral administration of tilsotolimod increases TIL
infiltration and checkpoint expression in both injected and distant
lesions creating a favorable tumor microenvironment to enhance the
antitumor activity of checkpoint inhibitors. Specifically in
this study, it was found that the combination of tilsotolimod with
checkpoint inhibitors targeting IDO-1 and PD-1 induced maximal
antitumor efficacy and eradicated large established tumors both
treated and distant, in preclinical models compared to either agent
alone as well as combinations of IDO-1 inhibitor and anti-PD-1.
“The results from this study further elucidate the mechanism of
tilsotolimod to stimulate an immune response and highlight the
utility of complementing checkpoint inhibition with immune
stimulation achievable with intratumoral TLR9 agonism yielding more
robust tumor regression,” stated Jonathan Yingling Idera’s Senior
Vice President, Chief Scientific Officer. “We’ve been
steadily building the pre-clinical, translational and clinical
datasets for tilsotolimod and are looking forward to our next data
update from the ILLUMINATE-204 trial in anti-PD-1 refractory
metastatic melanoma at the upcoming American Society of Clinical
Oncology (ASCO) meeting in June.”
A copy of the poster presentations are currently available on
Idera’s corporate website at
http://www.iderapharma.com/our-approach/key-publications/.
About Tilsotolimod (IMO-2125)Tilsotolimod
received orphan drug designation from the US Food and Drug
Administration (FDA) in 2017 for the treatment of melanoma Stages
IIb to IV. Tilsotolimod, in combination with ipilimumab, for PD-1
inhibitor refractory metastatic melanoma was granted fast track
application by the FDA in 2017. Tilsotolimod is a toll-like
receptor (TLR) 9 agonist that signals the immune system to create
and activate cancer-fighting cells (T-cells). Currently approved
immuno-oncology treatments for patients with metastatic melanoma,
specifically check-point inhibitors, work for some but not all, as
many patients’ immune response is missing or weak and thus they do
not benefit from the checkpoint therapy making them so-called
“refractory”. The combination of ipilimumab and tilsotolimod
appears to activate an immune response in these patients who have
exhausted all options. Intratumoral injections with tilsotolimod
are designed to selectively enable the T-cells to recognize and
attack cancers that remained elusive and unrecognized by the immune
system exposed to checkpoint inhibitors alone, while limiting
toxicity or impact on healthy cells in the
body. About
Idera PharmaceuticalsHarnessing the approach of the
earliest researchers in immunotherapy and the Company’s vast
experience in developing proprietary immunology platforms, Idera’s
lead development program is focused on priming the immune system to
play a more powerful role in fighting cancer, ultimately increasing
the number of people who can benefit from immunotherapy. Idera
continues to invest in research and development, and is committed
to working with investigators and partners who share the common
goal of addressing the unmet needs of patients suffering from rare,
life-threatening diseases. To learn more about Idera, visit
www.iderapharma.com.
Forward Looking StatementsThis press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. All statements,
other than statements of historical fact, included or incorporated
in this press release, including statements regarding the Company's
strategy, future operations, collaborations, intellectual property,
cash resources, financial position, future revenues, projected
costs, prospects, plans, and objectives of management, are
forward-looking statements. The words "believes," "anticipates,"
"estimates," "plans," "expects," "intends," "may," "could,"
"should," "potential," "likely," "projects," "continue," "will,"
and "would" and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Idera cannot guarantee
that it will actually achieve the plans, intentions or expectations
disclosed in its forward-looking statements and you should not
place undue reliance on the Company's forward-looking statements.
There are a number of important factors that could cause Idera's
actual results to differ materially from those indicated or implied
by its forward-looking statements. Factors that may cause such a
difference include: whether interim results from a clinical trial,
such as preliminary results reported in this release, will be
predictive of the final results of the trial, whether results
obtained in preclinical studies and clinical trials such as the
preclinical data described in this release will be indicative of
the results that will be generated in future clinical trials,
including in clinical trials in different disease indications;
whether products based on Idera's technology will advance into or
through the clinical trial process on a timely basis or at all and
receive approval from the United States Food and Drug
Administration or equivalent foreign regulatory agencies; whether,
if the Company's products receive approval, they will be
successfully distributed and marketed; and such other important
factors as are set forth under the caption "Risk Factors" in the
Company's Annual Report on form 10K for the period ended December
31, 2017. Although Idera may elect to do so at some point in the
future, the Company does not assume any obligation to update any
forward-looking statements and it disclaims any intention or
obligation to update or revise any forward-looking statement,
whether as a result of new information, future events or
otherwise.
Investor and Media ContactRobert DoodyVice
President, Investor Relations and Corporate CommunicationsOffice:
617-679-5515Mobile: 484‐639‐7235rdoody@iderapharma.com
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Apr 2023 to Apr 2024